IP Library Granted Patent US 10,570,430
Granted Patent B2
US 10,570,430 · App. 15/224,047 · Granted Feb 25, 2020

Metabolically engineered organisms for the production of added value bio-products

Inventors: Jo Maertens (Ghent, BE); Joeri Beauprez (Bredene, BE); Marjan De Mey (Ghent, BE)
Assignee: INBIOSE N.V.
C12P19/14C12N9/1051C12N9/2431C12N9/90C12N15/52C12N15/70C12N15/81C12P19/18C12P19/305C12Y204/01007C12Y204/01008C12Y204/01022C12Y204/01069C12Y302/01026C12Y504/02002
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,570,430
App. No.
15/224,047
Granted
Feb 25, 2020
Kind
B2
Abstract

The present invention relates to genetically engineered organisms, especially microorganisms such as bacteria and yeasts, for the production of added value bio-products such as specialty saccharide, activated saccharide, nucleoside, glycoside, glycolipid or glycoprotein. More specifically, the present invention relates to host cells that are metabolically engineered so that they can produce said valuable specialty products in large quantities and at a high rate by bypassing classical technical problems that occur in biocatalytical or fermentative production processes.

Claims (41)

1. A metabolically engineered bacterium or yeast for the production of a fucosyllactose, characterized in that said bacterium or yeast:

a) has been genetically modified by introducing a heterologous gene encoding a carbohydrate hydrolase capable of splitting sucrose into glucose and fructose;

b) comprises a glucokinase to catalyze conversion of glucose to glucose-6-phosphate;

c) comprises a fructokinase to catalyze conversion of fructose to fructose-6-phosphate;

d) has been further genetically modified to prevent loss of fructose-6-phosphate via glycolysis due to the genetic disruption of an endogenous gene encoding a phosphofructokinase, a phosphoglucose isomerase, or a combination thereof; and

e) comprises the following enzymes which convert said fructose-6-phosphate into a fucosyllactose:

(i) a mannose-6-phosphate isomerase to catalyze conversion of fructose-6-phosphate to mannose-6-phosphate;

(ii) a phosphomannomutase to catalyze conversion of mannose-6-phosphate to mannose-1-phosphate;

(iii) a mannose-1-phosphate guanylyltransferase to catalyze conversion of mannose-1-phosphate to GDP-mannose;

(iv) a GDP mannose dehydratase to catalyze conversion of GDP-mannose to GDP-4-dehydro-6-deoxy-mannose;

(v) a GDP fucose synthase to catalyze conversion of GDP-4-dehydro-6-deoxy-mannose to GDP-fucose; and

(vi) a fucosyltransferase to catalyze conversion of GDP-fucose to a fucosyllactose.

2. The metabolically engineered bacterium or yeast according to claim 1 , wherein said carbohydrate hydrolase is an invertase.

3. The metabolically engineered bacterium or yeast according to claim 1 , wherein said bacterium or yeast is further genetically modified with introduction of one or more heterologous genes encoding one or more enzymes which enhance the conversion of said fructose-6-phosphate into said fucosyllactose.

4. The metabolically engineered bacterium or yeast according to claim 1 , wherein said bacterium is Escherichia coli or wherein said yeast is Saccharomyces cereviseae.

5. The metabolically engineered bacterium or yeast of claim 1 , wherein the metabolically engineered bacterium or yeast has been genetically modified such that an endogenous gene encoding phosphofructokinase has been disrupted.

6. The metabolically engineered bacterium or yeast of claim 1 , wherein the metabolically engineered bacterium or yeast has been genetically modified such that an endogenous gene encoding phosphoglucose isomerase has been disrupted.

7. The metabolically engineered bacterium or yeast of claim 1 , wherein the metabolically engineered bacterium or yeast has been genetically modified such that each of an endogenous gene encoding phosphofructokinase and an endogenous gene encoding phosphoglucose isomerase has been disrupted.

8. The metabolically engineered bacterium or yeast of claim 1 , wherein the metabolically engineered bacterium or yeast is a metabolically engineered bacterium.

9. The metabolically engineered bacterium of claim 8 , wherein the bacterium is Escherichia coli.

10. The metabolically engineered bacterium or yeast of claim 1 , wherein the metabolically engineered bacterium or yeast is a metabolically engineered yeast.

11. The metabolically engineered yeast of claim 10 , wherein the yeast is Saccharomyces cerevisiae.

12. The metabolically engineered bacterium or yeast of claim 1 , wherein the fucosyllactose is selected from the group consisting of 1,2-fucosyllactose, 1,3-fucosyllactose, 1,4-fucosyllactose, 1,6-fucosyllactose, and any combination thereof.

13. The metabolically engineered bacterium or yeast of claim 1 , wherein the fucosyllactose is 1,2-fucosyllactose.

14. The metabolically engineered bacterium or yeast of claim 1 , wherein the fucosyllactose is 1,3-fucosyllactose.

15. The metabolically engineered bacterium or yeast of claim 1 , wherein the fucosyllactose is 1,4-fucosyllactose.

16. The metabolically engineered bacterium or yeast of claim 1 , wherein the fucosyllactose is 1,6-fucosyllactose.

17. The metabolically engineered bacterium or yeast of claim 1 , wherein said phosphofructokinase catalyzes conversion of fructose-6-phosphate to fructose-1,6-bisphosphate, and said phosphoglucose isomerase catalyzes the conversion of fructose-6-phosphate to glucose-6-phosphate.

18. The metabolically engineered bacterium or yeast of claim 3 , wherein the one or more enzymes encoded by the one or more heterologous genes are selected from the group consisting of: a mannose-6-phosphate isomerase, a phosphomannomutase, a mannose-1-phosphate guanylyltransferase, a GDP mannose dehydratase, a GDP fucose synthase, and a fucosyltransferase.

19. The metabolically engineered bacterium or yeast of claim 3 , wherein the metabolically engineered bacterium or yeast has been genetically modified such that an endogenous gene encoding phosphofructokinase has been disrupted.

20. The metabolically engineered bacterium or yeast of claim 3 , wherein the metabolically engineered bacterium or yeast has been genetically modified such that an endogenous gene encoding phosphoglucose isomerase has been disrupted.

21. The metabolically engineered bacterium or yeast of claim 3 , wherein the metabolically engineered bacterium or yeast has been genetically modified such that each of an endogenous gene encoding phosphofructokinase and an endogenous gene encoding phosphoglucose isomerase has been disrupted.

22. The metabolically engineered bacterium or yeast of claim 3 , wherein the metabolically engineered bacterium or yeast is a metabolically engineered bacterium.

23. The metabolically engineered bacterium of claim 22 , wherein the bacterium is Escherichia coli.

24. The metabolically engineered bacterium or yeast of claim 3 , wherein the metabolically engineered bacterium or yeast is a metabolically engineered yeast.

25. The metabolically engineered yeast of claim 24 , wherein the yeast is Saccharomyces cerevisiae.

26. The metabolically engineered bacterium or yeast of claim 3 , wherein the fucosyllactose is selected from the group consisting of 1,2-fucosyllactose, 1,3-fucosyllactose, 1,4-fucosyllactose, 1,6-fucosyllactose, and any combination thereof.

27. The metabolically engineered bacterium or yeast of claim 3 , wherein the fucosyllactose is 1,2-fucosyllactose.

28. The metabolically engineered bacterium or yeast of claim 3 , wherein the fucosyllactose is 1,3-fucosyllactose.

29. The metabolically engineered bacterium or yeast of claim 3 , wherein the fucosyllactose is 1,4-fucosyllactose.

30. The metabolically engineered bacterium or yeast of claim 3 , wherein the fucosyllactose is 1,6-fucosyllactose.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2017
From: UNIVERSITEIT GENT
To: INBIOSE N.V.
Reel/Frame 043926/0609 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 30, 2016
From: MAERTENS, JO; BEAUPREZ, JOERI; MEY, MARJAN DE
To: UNIVERSITEIT GENT
Reel/Frame 039904/0096 →
Priority Claims (1)
EP 10169304 · Jul 12, 2010 · regional
Continuity (2)
Division 13809340
Related Publication 20170016038A1 · Jan 19, 2017